We are international
Donate
TEXT SIZE   

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
    next      view all

More on Measles Virotherapy for Myeloma
Last week, the popular radio show Science Friday broadcast on National Public Radio explored the exciting science around cancer virotherapy. Guest Dr. Stephen Russell of the Mayo Clinic shared his experience treating myeloma patients with massive doses of the measles virus, which Dr. Durie has blogged about in the past. eek, the popular radio show Science Friday broadcast on National Public Radio explored the exciting science around cancer virotherapy. Guest Dr. Stephen Russell of the Mayo Clinic shared his experience treating myeloma patients with massive doses of the measles virus, which Dr. Durie has blogged about in the past.

MRD Testing: Have We Found the Method We Need?
Two types of tests are currently in development to measure minimal residual disease (MRD) in myeloma patients: a sophisticated new flow cytometry test and a molecular test. In his blog this week, IMF Chairman Dr. Brian Durie examines the differences between the two and explains why, in his opinion, the flow cytometry test is superior.

Register for the Living Well with Myeloma: Understanding the Immune System and Lab Values in Myeloma teleconference
The IMF's popular Living Well with Myeloma teleconference series returns on August 28th, with "Understanding the Immune System and Lab Values in Myeloma." The discussion and Q&A will be led by IMF Nurse Leadership Board member Ann McNeill, RN, MSN, APRN-C, Multiple Myeloma Division, Hackensack University Medical Center. The free teleconference will be held on Thursday, August 28th at 7 pm ET/ 4 pm PT.

FDA Approves Use of Velcade for Retreatment of Myeloma
The US FDA has approved the use of Velcade for retreatment of myeloma patients who have previously responded to Velcade and have relapsed at least six months after their prior treatment. The expanded approval was granted based on data from a phase II clinical trial. This approval includes IV and subcutaneous forms of Velcade.

Cancer Cases Among 9/11 Early Responders Continue to Grow
More cancer cases are being reported among 9/11 rescuers and responders, with more than 2,500 people with cancer now included in World Trade Center health programs. Myeloma is covered under the 9/11 Victim Compensation Fund, and studies have shown that 9/11 workers have gotten myeloma at a higher rate than expected in the normal population. Research has also shown a relationship between myeloma and exposure to carcinogens located at the World Trade Center site. IMF Chairman Dr. Brian Durie has written extensively on myeloma and toxins, and in his blog this week, he examines this troubling growth in cases.

#AskDrDurie: Is it okay to take vitamin B12 on the same day as Velcade?

In this episode of #AskDrDurie, Dr. Brian Durie of the IMF answers a myeloma patient’s question about taking a supplement like vitamin B12 on the same day as Velcade.


Summer 2014 Edition of Myeloma Today

Articles include:

  • Key Questions 2014: Highlights from the 5th Annual IMWG Summit
  • Highlights from the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO)
  • Living Well With Myeloma:  Expert Advice on Pain Management


Raise Your Voice: Advocacy 202 - Replay
Did you miss the Raise Your Voice: Advocacy 202 webinar last month? Have no fear, you can watch, listen and learn right from your computer today! The webinar focused on how to meet with your Member of Congress and ask for support of HR 1801, The Cancer Drug Coverage Parity Act and S 1879, The Cancer Treatment Parity Act. With enough voices, we can improve the quality of life for myeloma patients by building support for equal access to treatment. Watch the webinar to learn how you can make a difference.

The International Myeloma Foundation (IMF) Celebrates Maine’s Oral Anticacer Treatment Access Law Taking Effect

The International Myeloma Foundation (IMF) – improving the quality of life of myeloma patients while working toward prevention and a cure –  today celebrates Maine’s Oral Anticancer Treatment Access Law taking effect. The law directs health benefit plans that provide coverage for cancer chemotherapy treatment to extend coverage for orally administered anticancer medications at a cost equal to the cost of intravenously administered or injected anticancer medications. 


Frontline Therapy and MRD: Exciting New Data from France
Minimal residual disease (MRD) measurement through flow cytometry was shown to be a meaningful predictor in a frontline myeloma study published this month in the Journal of Clinical Oncology. In his blog, IMF Chairman Dr. Brian Durie explains that patients who achieved MRD-negative status remain in remission after a median follow-up of three years. This study “points the way to incorporation of MRD testing by flow cytometry into tailored approaches to achieve the very best results with therapy throughout the course of disease,” said Dr. Durie.

    next      view all